{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:08:50Z","timestamp":1761761330947,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFE0210400"],"award-info":[{"award-number":["2022YFE0210400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["M21003"],"award-info":[{"award-number":["M21003"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20241801"],"award-info":[{"award-number":["DFL20241801"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Although SARS-CoV-2 infection often follows a self-limiting course, its public health impact remains persistent. Older adults exhibit unique susceptibility to infection due to immunosenescence. Therefore, in order to offer recommendations for improving management options for older persons, this study intends to examine the immunological properties of NAb in the elderly population. Methods: Elderly patients aged 60 years and older infected during the prevalence of BF.7 and EG.5 variants were enrolled. The patterns of NAb responses in infected patients under both natural and vaccine-induced immunity were explored using bead-based proteomics techniques. The associations between NAb and IgG antibody levels, clinical characteristics, and traditional inflammatory indicators were evaluated using systematic analysis. Based on NAb levels, SARS-CoV-2 strains were immunologically classified. Results: There was a positive correlation between the severity of the disease and the strength of the NAb response. Because of more extensive immune activation, severe instances in elderly patients showed higher levels of NAb responses. When compared to the uninfected group, people who had received two doses of vaccination exhibited greater NAb levels. Additionally, there was a link between NAb and IgG levels, but as the virus evolved, this correlation progressively diminished. Three serotypes of SARS-CoV-2 were identified based on NAb response characteristics: pre-Omicron, Omicron, and XBB serotypes. Conclusions: The results show the features of NAb responses in older patients, which could help with the creation of future vaccines and public health initiatives.<\/jats:p>","DOI":"10.3390\/vaccines13111107","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:38:22Z","timestamp":1761759502000},"page":"1107","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutralizing Antibody Response Characteristics in Elderly Patients with SARS-CoV-2 Infection and Their Association with Clinical Phenotypes"],"prefix":"10.3390","volume":"13","author":[{"given":"Yunhui","family":"Li","sequence":"first","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Key Laboratory of Viral Infectious Diseases, Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Key Laboratory of Viral Infectious Diseases, Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Ma","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Key Laboratory of Viral Infectious Diseases, Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University Ditan Teaching Hospital, Beijing 100015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-2537","authenticated-orcid":false,"given":"Yajie","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Key Laboratory of Viral Infectious Diseases, Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1473-3099(24)00574-7","article-title":"Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron ba.2, ba.4\/5, and XBB dominance in Hong Kong: A prospective cohort study","volume":"25","author":"Wang","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41579-022-00722-z","article-title":"Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity","volume":"20","author":"Markov","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.arr.2022.101818","article-title":"Immunosenescence and inflamm-ageing in COVID-19","volume":"84","author":"Zinatizadeh","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s11357-024-01099-y","article-title":"Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: A comparative study from the national centre of hungary","volume":"46","author":"Gaspar","year":"2024","journal-title":"Geroscience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine bnt162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 bnt162b1 mRNA vaccine in younger and older Chinese adults: A randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to bnt162b2 COVID-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA bnt162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/acsinfecdis.5c00402","article-title":"A High-Throughput Broad Neutralizing Antibody Assay for Detecting SARS-CoV-2 Variant Immunity in Population","volume":"11","author":"Zhang","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106310","DOI":"10.1016\/j.jinf.2024.106310","article-title":"Synergistic evolution: The dynamic adaptation of SARS-CoV-2 and human protective immunity in the real world","volume":"89","author":"Li","year":"2024","journal-title":"J. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: An epidemiological and phylogenetic analysis","volume":"401","author":"Pan","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/bmj.p1900","article-title":"COVID-19: Infections climb globally as eg.5 variant gains ground","volume":"382","author":"Dyer","year":"2023","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1450196","DOI":"10.3389\/fcimb.2024.1450196","article-title":"Immunological characteristics in elderly COVID-19 patients: A post-COVID era analysis","volume":"14","author":"Li","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41423-020-00588-2","article-title":"A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity","volume":"18","author":"Legros","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"868361","DOI":"10.3389\/fimmu.2022.868361","article-title":"Immune responses against SARS-CoV-2 WT and delta variant in elderly bnt162b2 vaccinees","volume":"13","author":"Jager","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_20","first-page":"n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study","volume":"373","author":"Andrews","year":"2021","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S1473-3099(21)00289-9","article-title":"Vaccine effectiveness of the first dose of chadox1 ncov-19 and bnt162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study","volume":"21","author":"Shrotri","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41422-023-00781-8","article-title":"Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against omicron variants in breakthrough infection","volume":"33","author":"Gao","year":"2023","journal-title":"Cell Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.celrep.2022.110393","article-title":"B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination","volume":"38","author":"Kotagiri","year":"2022","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to jn.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gulova, S.M., Veselkina, U.S., and Astrakhantseva, I.V. (2025). Adaptation of the vaccine prophylaxis strategy to variants of the SARS-CoV-2 virus. Vaccines, 13.","DOI":"10.3390\/vaccines13070761"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106208","DOI":"10.1016\/j.jinf.2024.106208","article-title":"Repeated omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against omicron sub-variants","volume":"89","author":"Gong","year":"2024","journal-title":"J. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Roltgen","year":"2022","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40121-020-00324-3","article-title":"A systematic review of the clinical utility of cycle threshold values in the context of COVID-19","volume":"9","author":"Rao","year":"2020","journal-title":"Infect Dis Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"11","author":"Fajnzylber","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/eurheartj\/ehaa408","article-title":"Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019","volume":"41","author":"Shi","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"745515","DOI":"10.3389\/fimmu.2021.745515","article-title":"Basic predictive risk factors for cytokine storms in COVID-19 patients","volume":"12","author":"Shcherbak","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10238-021-00777-x","article-title":"Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: A systematic review and meta-analysis with meta-regression","volume":"22","author":"Zinellu","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/CIRCRESAHA.122.321952","article-title":"Interaction of COVID-19 with common cardiovascular disorders","volume":"132","author":"Boulos","year":"2023","journal-title":"Circ. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2170809","DOI":"10.1080\/0886022X.2023.2170809","article-title":"Risk factors for acute kidney injury in COVID-19 patients: An updated systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2402639","DOI":"10.1002\/advs.202402639","article-title":"SARS-CoV-2 evolution: Immune dynamics, omicron specificity, and predictive modeling in vaccinated populations","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41392-025-02139-5","article-title":"Recombinant xbb.1.5 boosters induce robust neutralization against kp.2- and kp.3-included jn.1 sublineages","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-025-02132-y","article-title":"Neutralizing antibody responses to three XBB protein vaccines in older adults","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:03:58Z","timestamp":1761761038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111107"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111107","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}